



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 2/21/2019
LAST REVIEW DATE: 2/18/2021
LAST CRITERIA REVISION DATE: 2/13/2020
ARCHIVE DATE:

VIZIMPRO® (dacomitinib) oral tablet

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 2/21/2019
LAST REVIEW DATE: 2/18/2021
LAST CRITERIA REVISION DATE: 2/13/2020
ARCHIVE DATE:

VIZIMPRO® (dacomitinib) oral tablet

Criteria:

- **Criteria for initial therapy:** Vizimpro (dacomitinib) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Oncologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of ONE of the following:
 - a. Metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion **OR** exon 21 L858R substitution mutations
 - b. Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
 4. Individual does not have severe renal impairment (CrCl < 30 mL/min) or on hemodialysis
 5. Individual does not have severe hepatic impairment (total bilirubin > 3-10 x ULN and any AST)
 6. **ALL** of the following baseline tests have been completed before initiation of treatment:
 - a. Detection of EGFR exon 19 deletion **OR** exon 21 L858R substitution mutations
 - b. Liver function tests
 - c. Creatinine clearance
 - d. Negative pregnancy test in a woman of reproductive potential

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Vizimpro (dacomitinib) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with Oncologist
 2. Individual's condition has not worsened while on therapy
 3. Individual has been adherent with the medication
 4. Individual does not have severe renal impairment (CrCl < 30 mL/min) or on hemodialysis
 5. Individual does not have severe hepatic impairment (total bilirubin > 3-10 x ULN and any AST)
 6. Individual has not developed any significant level 4 adverse drug effects that may exclude continued use
 - a. Significant adverse effect such as:



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 2/21/2019
LAST REVIEW DATE: 2/18/2021
LAST CRITERIA REVISION DATE: 2/13/2020
ARCHIVE DATE:

VIZIMPRO® (dacomitinib) oral tablet

i. Interstitial lung disease

7. There are no significant interacting drugs

Renewal duration: 6 months

Description:

Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation).

Resources:

Vizimpro (dacomitinib) product information, revised by Pfizer Laboratories Div Pfizer, Inc. 12-2020, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed January 31, 2021.

Vizimpro (dacomitinib). National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium. 2021; Available at: <http://www.nccn.org>. Accessed January 31, 2021.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.
